ANDAs Showing Steady Improvement In First-Cycle Approval Times
Executive Summary
First-cycle approvals took longer than multi-cycle approvals in the generic drug user fee program's first year, but decreased dramatically in year two.
You may also be interested in...
Candidates For The US FDA’s STAR Program Might As Well Be Breakthrough Therapies, Too
The requirements to join the new real-time review pilot program strongly resemble those of the breakthrough designation, which could come as an unpleasant surprise for some sponsors.
US FDA Likely To Embrace In-Person, Remote Combo For Facility Inspections Going Forward
System likely will evolve as post-pandemic world unfolds, but adds to list of agency programs expecting to continue using virtual platforms once in-person activities are no longer restricted by COVID-19.